Story’s next chapter begins
Revenio’s investor story remains interesting, as the strategy’s next phase begins after the acquisition of CenterVue. The core business continues to grow very profitably, the underlying market has strong structural growth drivers, and the products have exceptionally strong competitive advantages. Revenio has also shown over the years how capable they are in value creation through investments into product development, structural transitions, and long-term growth development projects.
Login required
This content is only available for logged in users
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures01.10.2019
2018 | 19e | 20e | |
---|---|---|---|
Revenue | 30.7 | 50.1 | 67.0 |
growth-% | 14.55 % | 63.36 % | 33.85 % |
EBIT (adj.) | 10.2 | 14.3 | 21.2 |
EBIT-% (adj.) | 33.27 % | 28.49 % | 31.60 % |
EPS (adj.) | 0.34 | 0.47 | 0.63 |
Dividend | 0.28 | 0.34 | 0.44 |
Dividend % | 2.23 % | 1.20 % | 1.55 % |
P/E (adj.) | 36.92 | 59.94 | 45.09 |
EV/EBITDA | 27.10 | 64.17 | 33.73 |